For example, one could speculate that removal of the growth-promoting Her2 receptor from breast cancer cells via macrophage trogocytosis of trastuzumab/Her2 complexes might actually help to reduce tumour cell survival, thereby enhancing the efficacy of trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.